American Kidney Fund Launches Grant Program to Accelerate Rare Kidney Disease Diagnosis
Event summary
- American Kidney Fund (AKF) convenes its 7th annual UCKD Summit on October 2, 2026, focusing on early recognition of rare and genetic kidney diseases.
- AKF announces a new Quality of Care Innovations in Chronic Kidney Disease (CKD) grant program to fund projects accelerating early identification of CKD.
- Applications for the grant program will be open from October 2026 through February 2027.
- Keynote speaker Dr. Janewit Wongboonsin discusses genetic signatures of nephrotic syndrome and diagnostic differences between the U.S. and U.K.
The big picture
The AKF's UCKD Summit and grant program highlight the growing focus on rare and genetic kidney diseases, addressing a critical gap in early diagnosis. With 15% of kidney disease cases having unknown causes, the initiative aims to reduce health disparities and empower patients through better diagnostic resources. The involvement of major pharmaceutical partners underscores the industry's commitment to advancing kidney disease research and care.
What we're watching
- Grant Impact
- Whether the new grant program will effectively reduce diagnostic delays and improve early identification of CKD.
- Industry Collaboration
- How the involvement of pharmaceutical partners will shape the direction and success of the UCKD Project.
- Diagnostic Advancements
- The pace at which genetic testing and diagnostic tools will be integrated into standard kidney disease care.